Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

Benzinga · 2d ago
Baird analyst Joel Beatty maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $28 to $52.